Everett Harris & Co. CA Decreases Position in AbbVie Inc. $ABBV

Everett Harris & Co. CA decreased its position in AbbVie Inc. (NYSE:ABBV) by 0.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 517,834 shares of the company’s stock after selling 3,425 shares during the period. AbbVie comprises approximately 1.5% of Everett Harris & Co. CA’s portfolio, making the stock its 15th biggest holding. Everett Harris & Co. CA’s holdings in AbbVie were worth $119,899,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of ABBV. Trifecta Capital Advisors LLC raised its stake in shares of AbbVie by 2.3% in the third quarter. Trifecta Capital Advisors LLC now owns 39,928 shares of the company’s stock valued at $9,245,000 after buying an additional 900 shares during the period. Cahill Financial Advisors Inc. raised its stake in AbbVie by 8.2% in the 3rd quarter. Cahill Financial Advisors Inc. now owns 3,046 shares of the company’s stock valued at $705,000 after acquiring an additional 231 shares during the period. Knights of Columbus Asset Advisors LLC lifted its holdings in AbbVie by 121.3% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 2,700 shares of the company’s stock valued at $625,000 after purchasing an additional 1,480 shares during the last quarter. Asset Allocation & Management Company LLC purchased a new stake in AbbVie during the third quarter valued at about $219,000. Finally, Pittenger & Anderson Inc. boosted its position in AbbVie by 3.0% during the third quarter. Pittenger & Anderson Inc. now owns 28,722 shares of the company’s stock worth $6,650,000 after purchasing an additional 839 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

NYSE:ABBV opened at $220.42 on Friday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The stock has a fifty day moving average of $224.67 and a 200 day moving average of $218.02. The firm has a market capitalization of $389.56 billion, a price-to-earnings ratio of 166.98, a P/E/G ratio of 0.90 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm posted $3.00 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of recent research reports. The Goldman Sachs Group restated a “neutral” rating and set a $223.00 price target on shares of AbbVie in a research note on Wednesday. Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 price target (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. Erste Group Bank downgraded AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, Berenberg Bank set a $275.00 target price on AbbVie in a report on Tuesday, January 20th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $249.37.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Investor enthusiasm around a reported bispecific trial win and management’s renewed R&D pledge — this strengthens AbbVie’s pipeline narrative and long-term growth prospects. Does AbbVie’s Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?
• Positive Sentiment: Retrospective coverage highlighting AbbVie’s strong 2025 performance reinforces confidence in management’s handling of patent cliffs and portfolio transitions. Why AbbVie Stock Trounced the Market in 2025
• Positive Sentiment: Allergan Aesthetics unveiled new clinical and portfolio data that support continued strength in the aesthetics business — a valuable, higher-margin growth pillar for AbbVie. Allergan Aesthetics Unveils New Data Across Facial Injectables
• Positive Sentiment: On-air analyst commentary recommended staying long ABBV, adding short-term buying pressure from retail and institutional viewers. AbbVie, SLB, Amphenol, And More On CNBC’s ‘Final Trades’
• Neutral Sentiment: Coverage of AbbVie’s drug affordability deal notes management is trying to balance price/access commitments with continued R&D and patient-growth plans — reduces regulatory risk but may cap pricing upside. AbbVie Balances Drug Affordability Deal With R&D And Patient Growth Plans
• Neutral Sentiment: Investor note questioning whether recent gains leave ABBV fairly priced based on DCF and price-to-sales signals — flags valuation scrutiny even as shares rally. Is AbbVie (ABBV) Pricing Reflect Its DCF And Price To Sales Signals After Recent Gains
• Neutral Sentiment: AbbVie launched a migraine-focused awareness program (“Love in Mind”) — positive for brand, patient engagement and uptake of migraine therapies but largely a longer-term marketing play. AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine
• Negative Sentiment: Near-term earnings preview from Zacks suggests AbbVie may lack the setup for an earnings beat next week, which could increase volatility if guidance or execution disappoints. AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.